BioMarin Pharmaceutical, Inc. (BMRN)
57.23
+0.53
(+0.93%)
USD |
NASDAQ |
Nov 13, 16:00
57.31
+0.08
(+0.14%)
After-Hours: 19:59
BioMarin Pharmaceutical Enterprise Value : 14.45B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 14.45B |
| November 11, 2026 | 14.77B |
| November 10, 2026 | 14.53B |
| November 09, 2026 | 14.54B |
| November 06, 2026 | 14.32B |
| November 05, 2026 | 14.34B |
| November 04, 2026 | 14.53B |
| November 03, 2026 | 14.25B |
| November 02, 2026 | 14.59B |
| October 30, 2026 | 14.80B |
| October 29, 2026 | 14.60B |
| October 28, 2026 | 14.32B |
| October 27, 2026 | 14.19B |
| October 26, 2026 | 14.27B |
| October 23, 2026 | 14.31B |
| October 22, 2026 | 14.44B |
| October 21, 2026 | 14.16B |
| October 20, 2026 | 14.40B |
| October 19, 2026 | 14.06B |
| October 16, 2026 | 14.06B |
| October 15, 2026 | 14.33B |
| October 14, 2026 | 14.15B |
| October 13, 2026 | 14.00B |
| October 12, 2026 | 14.20B |
| October 09, 2026 | 14.08B |
| Date | Value |
|---|---|
| October 08, 2026 | 14.10B |
| October 07, 2026 | 14.16B |
| October 06, 2026 | 14.36B |
| October 05, 2026 | 14.61B |
| October 02, 2026 | 14.54B |
| October 01, 2026 | 14.79B |
| September 30, 2026 | 15.09B |
| September 29, 2026 | 14.93B |
| September 28, 2026 | 14.85B |
| September 25, 2026 | 15.01B |
| September 24, 2026 | 15.22B |
| September 23, 2026 | 15.38B |
| September 22, 2026 | 15.61B |
| September 21, 2026 | 15.74B |
| September 18, 2026 | 15.72B |
| September 17, 2026 | 15.94B |
| September 16, 2026 | 15.87B |
| September 15, 2026 | 15.82B |
| September 14, 2026 | 16.20B |
| September 11, 2026 | 16.06B |
| September 10, 2026 | 16.02B |
| September 09, 2026 | 15.81B |
| September 08, 2026 | 15.85B |
| September 04, 2026 | 16.22B |
| September 03, 2026 | 16.20B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exelixis, Inc. | 16.36B |
| Ascendis Pharma A/S | 17.13B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
| Cytokinetics, Inc. | 7.958B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -122.83M |
| Revenue (Quarterly) | 1.025B |
| Total Expenses (Quarterly) | 1.147B |
| EPS Diluted (Quarterly) | -0.6345 |
| Gross Profit Margin (Quarterly) | 70.24% |
| Profit Margin (Quarterly) | -11.99% |
| Earnings Yield | -0.18% |
| Operating Earnings Yield | 6.37% |
| Normalized Earnings Yield | 3.334 |